| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |